CD274 and cancer: Such cancer cell variants may survive immunosurveillance and progress toward the equilibrium phase, where cancer cells remain functionally dormant or continue to evolve into new subclones harboring immune escape mutations such as a loss of antigen presentation and an increased expression of programmed death ligand-1 (PD-L1) [16,19,20].